Formoterol inhalation - Mylan Specialty

Drug Profile

Formoterol inhalation - Mylan Specialty

Alternative Names: Formoterol fumarate inhalation solution - Dey; Nebulised formoterol fumarate - Dey; Perforomist; Perforomist Inhalation Solution

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dey LP
  • Developer Mylan Specialty
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 17 Apr 2015 The United States Court of Appeals for the Federal Circuit upholds Mylan's U.S. Patents on formoterol inhalation solution
  • 24 Jul 2013 Biomarkers information updated
  • 19 May 2009 Pooled efficacy & adverse events data from 2 phase III trials in Chronic obstructive pulmonary disease presented at the 105th International Conference of the American Thoracic Society (ATS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top